Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 342 participants.

Also called NCT01032395

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 342 participants (enrolled count) (from the registry)
Sponsor
Chiltern Pesquisa Clinica Ltda (from the registry)
Registry
  • NCT NCT01032395
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01032395. Randomized; no masking; primary purpose prevention. Start 2010-03 (registry gives no type); primary completion 2011-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
Condition
H1N1 Influenza Virus
Condition
Chronic Pulmonary Disease
Condition
Chronic Heart Disease
Condition
Diabetes Mellitus
Intervention (Biological)
Focetria®
Intervention (Biological)
Fluad®
Intervention (Biological)
Begrivac®
Lead sponsor
Chiltern Pesquisa Clinica Ltda (class: industry)

Record details

Record id
cardio:ct-nct01032395
Content hash
6945e700ce658f296fd4863d46628d0b1875fd0a38f2412e19c4d7a73ca5e009